StockData
Keros Therapeutics, Inc. logo

Keros Therapeutics, Inc. (KROS) stock

KROSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/30
$12.00+0.69 (+6.10%)

Close on Nov 18, 2026Market cap $237.93MP/E –Yield –

Keros Therapeutics price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Keros Therapeutics's price to sales ratio was 13.0× on Nov 11, 2026, against 2.9× a year earlier. Over the last 3 years it ranged from 0.9× to 460.6×, with a median of 7.2×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 202613.0×+9.6
2025Dec 31, 20253.4×−59.8
2022Apr 29, 202263.2×−397.4
2021Jan 29, 2021460.6×+236.5
2020Oct 30, 2020224.2×–

More Keros Therapeutics figures

See a number that looks wrong?